Liu Xiangyu, Wang Xinxing, Li Jian, Zhao Zhongjie, Liu Yan, Li Xiaolu, Wang Wentao, Wang Qianqian, Sun Xiaozhi, Guo Mingjin, Yu Tao, Li Yongxin
Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, People's Republic of China.
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, People's Republic of China.
Research (Wash D C). 2025 Nov 26;8:1019. doi: 10.34133/research.1019. eCollection 2025.
Postinjury restenosis is a common complication of peripheral arterial disease treated via endovascular techniques. Its pathogenesis mainly involves neointimal hyperplasia and persistent inflammation. Although antiproliferative drugs used clinically can temporarily slow restenosis, their effects are limited by short action duration and lack of precise regulation. In this investigation, tRF-49:69-chrM.Trp-TCA (tRF-Trp-TCA) was identified through sequencing data from an animal restenosis model, and its regulatory effects on endothelial cell migration and inflammation were confirmed. Additionally, we discovered that cabbage exosome-like nanoparticles (CELNs) could precisely target injured blood vessels in vivo, enhance the stability of nucleic acid therapeutics, and more effectively inhibit neointimal hyperplasia in a carotid artery balloon injury model. Our results demonstrated that tRF-Trp-TCA is crucial in restenosis induced by arterial injury and CELNs loaded with tRF-Trp-TCA effectively inhibit neointimal hyperplasia following carotid artery injury in rats, showing good biocompatibility. This study has, for the first time, identified the target tRF-Trp-TCA for treating restenosis after vascular injury and has also, for the first time, used CELNs as the delivery system. This discovery could provide new insights for noninvasive treatments or mitigation of restenosis post-endovascular therapy.
损伤后再狭窄是通过血管内技术治疗的外周动脉疾病的常见并发症。其发病机制主要涉及新生内膜增生和持续性炎症。虽然临床上使用的抗增殖药物可暂时减缓再狭窄,但它们的作用受到作用持续时间短和缺乏精确调控的限制。在本研究中,通过动物再狭窄模型的测序数据鉴定出了tRF-49:69-chrM.Trp-TCA(tRF-Trp-TCA),并证实了其对内皮细胞迁移和炎症的调控作用。此外,我们发现甘蓝外泌体样纳米颗粒(CELNs)能够在体内精确靶向损伤血管,增强核酸治疗药物的稳定性,并在颈动脉球囊损伤模型中更有效地抑制新生内膜增生。我们的结果表明,tRF-Trp-TCA在动脉损伤诱导的再狭窄中起关键作用,负载tRF-Trp-TCA的CELNs可有效抑制大鼠颈动脉损伤后的新生内膜增生,具有良好的生物相容性。本研究首次确定了治疗血管损伤后再狭窄的靶点tRF-Trp-TCA,也首次将CELNs用作递送系统。这一发现可为无创治疗或减轻血管内治疗后的再狭窄提供新的见解。